A Multicenter Phase I/II Trial of APG-115 in P53 Wild-Type Salivary Gland Carcinoma

Condition:   Malignant Salivary Gland Cancer
Interventions:   Drug: APG115 mono-therapy;   Drug: APG115 + Carboplatin;   Other: Part 2
Sponsors:   Ascentage Pharma Group Inc.;   University of Michigan
Not yet recruiting

https://ift.tt/2LsJQMT